Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24019582 | 0.84 | ALDH1A1 (0.79) | HPGDALDH1A1TSHRGAANPSR1 | |
| SCHEMBL24019616 | 0.82 | ALDH1A1 (0.77) | HPGDALDH1A1TSHRGAANPSR1 | |
| SCHEMBL25609885 | 0.82 | ALDH1A1 (0.58) | HPGDALDH1A1TSHRGAANPSR1 | |
| SCHEMBL24210125 | 0.81 | ALDH1A1 (0.71) | HPGDALDH1A1TSHRNPSR1KMT2A | |
| SCHEMBL24209750 | 0.81 | ALDH1A1 (0.71) | HPGDALDH1A1TSHRNPSR1KMT2A | |
| SCHEMBL21951986 | 0.80 | MAPT (0.71) | HPGDALDH1A1TSHRGAANPSR1 | |
| SCHEMBL24209629 | 0.80 | ALDH1A1 (0.54) | HPGDALDH1A1TSHRGAANPSR1 | |
| SCHEMBL24019584 | 0.80 | ALDH1A1 (0.70) | HPGDALDH1A1TSHRNPSR1MEN1 | |
| SCHEMBL24019591 | 0.79 | SMN1; SMN2 (0.69) | HPGDALDH1A1GAANPSR1MEN1 | |
| SCHEMBL22009686 | 0.79 | HPGD (0.67) | HPGDALDH1A1TSHRNPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | XIAP, UBQLN1, MDM2 | HPGD 2761/4885ALDH1A1 1206/4885TSHR 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.